KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Morning versus afternoon administration of immune checkpoint inhibitors in metastatic non-small-cell lung cancer. PMID 42134900 · J Immunother Cancer · 2026-May-14 The study is an observational analysis using real-world data to emulate a randomized trial, not a prospective Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention as defined by the criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Personalized machine learning-guided radiation dose escalation in newly diagnosed glioblastoma: prospective pilot study. PMID 42129213 · Nat Commun · 2026-May-13 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Does laser treatment affect outcome in pilonidal sinus disease? Long-term multicenter retrospective analysis of pit-picking alone vs. pit-picking with laser. PMID 42128975 · Tech Coloproctol · 2026-May-13 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effect of prolonged interval between neoadjuvant chemoradiotherapy and surgery on pathological and oncological outcomes in locally advanced rectal cancer: a randomized controlled trial. PMID 42128940 · Int J Colorectal Dis · 2026-May-13 The record is a randomized, oncology trial with drug intervention and time-to-event endpoints, but the trial phase (Phase II vs. Phase III) is not explicitly stated in the title, abstract, or publication metadata, preventing confirmation of the 'phase3_or_definitive' criterion.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10). PMID 42128502 · BMJ Open · 2026-May-13 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Chemotherapy followed by pelvic reirradiation versus chemotherapy alone as preoperative treatment for locally recurrent rectal cancer (GRECCAR 15): superiority open-label phase III randomized clinical trial. PMID 42126061 · Br J Surg · 2026-May-13 Metadata (title) establishes oncology, phase III, randomized, and drug intervention criteria. However, the absence of an abstract prevents confirmation of a time-to-event efficacy endpoint, the original-report nature of the document, and the human subject context. Therefore, eligibility cannot be definitively determined.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Health-related quality of life comparing standard and prolonged time-to-surgery after neoadjuvant chemoradiotherapy for esophageal cancer: results from the multicenter, randomized, controlled NeoRes II trial. PMID 42132923 · Dis Esophagus · 2026-May-12 The study is a randomized, controlled trial in oncology (esophageal cancer) but is a secondary/quality-of-life analysis. It does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc., or Kaplan-Meier/HR for such endpoints). Furthermore, the intervention is a timing comparison (standard vs. prolonged time-to-surgery) and not a drug-containing intervention; the neoadjuvant chemoradiotherapy is part of the standard of care for all patients, not a variable being tested. The abstract explicitly states the primary endpoints have been reported previously, and this report is a sub-study focused on quality of life.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Assessing a biomarker platform for stratifying indeterminate pulmonary nodules, protocol for the SPOT IT randomized trial. PMID 42121244 · Trials · 2026-May-12 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Intravenous Patient-Controlled Analgesia Versus Oral Opioids to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase III Trial. PMID 42119607 · J Natl Compr Canc Netw · 2026-May-12 The study is a randomized Phase III trial with a drug intervention (hydromorphone vs. morphine) in oncology patients. However, the primary efficacy endpoint is pain relief measured by the Numeric Rating Scale (NRS), which is not a time-to-event outcome (e.g., OS, PFS, DFS). No Kaplan-Meier curves or hazard ratios for time-to-event endpoints are reported.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Preoperative Stereotactic Body Radiotherapy for Metastatic Bone Disease With Impending Fracture: A Nonrandomized Clinical Trial. PMID 42119606 · J Natl Compr Canc Netw · 2026-May-12 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Risk-Benefit of Phase 2 Monotherapy Trials in Adult Solid Cancers: A Systematic Review and Meta-Analysis. PMID 42117884 · Int J Cancer · 2026-May-12 The record is a systematic review and meta-analysis comparing phase 2 and phase 3 trials, not an original report of a single randomized trial. It does not meet the criteria for a drug-containing intervention trial with a primary/key secondary time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Biochemical Recurrence Irradiation or Observation (BRIO) in patients with prostate cancer: protocol for a randomised control trial. PMID 42117295 · BJU Int · 2026-May-12 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Cardioprotective effects of platycodon grandiflorum granules in HER2-positive early breast cancer patients receiving trastuzumab plus pertuzumab: study protocol for a double blind randomized controlled trial. PMID 42116119 · BMC Complement Med Ther · 2026-May-12 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Shen-Ling-Lian-Xia Granule Combined With Neoadjuvant Chemotherapy in Patients With Triple-Negative Breast Cancer: Protocol for a Randomized, Double-Blind, Multicenter Clinical Trial. PMID 42219932 · JMIR Res Protoc · 2026-May-11 The record is a protocol for a randomized trial but does not report original results and uses a non-time-to-event primary endpoint. It is excluded as a protocol-without-results.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Encounter tool for Shared Decision Making about Adjuvant Treatment of Lung Cancer: Randomized Clinical Trial. PMID 42183367 · Res Sq · 2026-May-11 The record describes a planned randomized trial protocol for evaluating a shared decision-making tool, not a report of trial results. It lacks a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The phase is not definitively established as Phase III/IIIb or Phase II/III. Therefore, it does not meet the eligibility criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of digital exercise therapy and cognitive behavioral therapy on body image and social distance of postoperative patients with breast cancer: study protocol for a randomized controlled trial. PMID 42116180 · Trials · 2026-May-11 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Involved nodal versus elective neck radiotherapy (INVERT) for head and neck squamous cell carcinoma: a prospective phase II randomized controlled trial protocol. PMID 42116021 · BMC Cancer · 2026-May-11 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Phase 2 study of talabostat, a small molecule inhibitor of dipeptidyl peptidases (DPP), administered in combination with pembrolizumab in patients with small cell neuroendocrine prostate cancer. PMID 42114950 · J Immunother Cancer · 2026-May-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC): protocol for a randomised controlled trial. PMID 42114858 · BMJ Open · 2026-May-11 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Optimising a behavioural intervention to support endocrine therapy adherence for women with breast cancer: protocol for the ROSETA optimisation factorial randomised controlled trial. PMID 42108483 · Trials · 2026-May-11 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Discrepancies in Inter-Rater Agreement on Resectability of Recurrent Glioblastoma: Complementary Post-hoc Analysis of the Prospective, Randomized DIRECTOR Trial. PMID 42108589 · Neuro Oncol · 2026-May-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Intraoperative biodegradable stent placement to reduce complications after pancreatoduodenectomy - interim results from a randomised clinical trial. PMID 42104174 · Langenbecks Arch Surg · 2026-May-09 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Understanding randomized controlled trial generalizability through an embedded molecular diagnostics trial. PMID 42026952 · JNCI Cancer Spectr · 2026-May-09 The study is a randomized controlled trial (RCT) embedded within a genomic diagnostics trial for prostate cancer, but it is not a drug-intervention trial. It compares treatment patterns (secondary treatment rates and time to treatment) between trial participants and real-world cohorts, but the intervention is a genomic classifier, not a drug. The time-to-event endpoint is time to secondary treatment, but this is not a standard efficacy endpoint (e.g., OS, PFS, DFS) for a drug-containing intervention. The phase is not established as Phase III/IIIb or Phase II/III. Therefore, it does not meet the eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Placebo Response in Phase II-III Symptom Intervention Studies: A Focus on Chemotherapy-Induced Peripheral Neuropathy and Associated Neuropathic Pain. PMID 42192875 · Cancers (Basel) · 2026-May-08 The record describes a meta-analysis and pooled analysis of placebo response rates in multiple trials, not the primary results of a single Phase III randomized trial with a time-to-event efficacy endpoint. The study focuses on symptom outcomes (neuropathy response rates) and does not report OS, PFS, DFS, EFS, RFS, TTP, or Kaplan-Meier/HR analyses.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Noddings' caring theory-based intervention to enhance coping with death competence in advanced lung cancer patients: a randomized controlled trial. PMID 42101688 · Support Care Cancer · 2026-May-08 Eligibility fails due to the absence of a drug intervention and a time-to-event efficacy endpoint. The study is a randomized trial in advanced lung cancer, but the intervention is non-pharmacological, and outcomes are psychological, not tumor-related time-to-event endpoints like OS or PFS.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial. PMID 42098105 · Nat Commun · 2026-May-08 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Existential distress in advanced cancer: study protocol of a pragmatic randomized controlled trial of a short-term psychodynamic therapy (ORPHYS) compared to usual psycho-oncological treatment (TAU). PMID 42098804 · Trials · 2026-May-07 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Comparing keystone and Limberg flaps for pilonidal sinus: Does flap choice influence patient satisfaction? PMID 42098544 · Tech Coloproctol · 2026-May-07 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions (DESTINATION 2): protocol for a randomised, phase II/R-IDEAL2b trial. PMID 42097645 · BMJ Open · 2026-May-07 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Optimizing bone health in lymphoma survivors: denosumab superiority to alendronate for R-CHOP-like therapy (the DENOSULY phase III randomized controlled trial). PMID 42095246 · Haematologica · 2026-May-07 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H B
影子组漏检补回 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
A randomized controlled trial of metastasis-directed therapy for oligometastases in breast cancer: OLIGAMI trial (JCOG2110). PMID 41615067 · Jpn J Clin Oncol · 2026-May-07 The record describes a randomized controlled trial protocol for a Phase III (implied by the question of superiority) study of metastasis-directed therapy plus systemic drug therapy versus systemic drug therapy alone for oligometastatic breast cancer, with overall survival as the primary endpoint. However, it is a protocol abstract without reported results, the phase is not explicitly stated as Phase III/IIIb or Phase II/III, and while systemic drug therapy is part of the intervention, it is not specified as a drug-containing intervention in a way that can be confirmed from the abstract alone (it could be non-drug therapy). Therefore, it does not meet the criteria for an original formal-result report of a randomized trial with a drug-containing intervention.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia. PMID 41525466 · Blood · 2026-May-07 The study reports on a gene therapy for transfusion-dependent β-thalassemia, a hematologic disorder but not a malignant neoplasm. The primary efficacy outcomes are transfusion independence and hemoglobin levels, which are not time-to-event endpoints like OS, PFS, or DFS. While the study includes a phase 3 component and reports long-term efficacy results, it fails the fundamental oncology criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Current and emerging therapies in IDH-mutant glioma. PMID 42085879 · Neurotherapeutics · 2026-May-04 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma. PMID 42082272 · J Immunother Cancer · 2026-May-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancer. PMID 42082271 · J Immunother Cancer · 2026-May-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy of Renin-Angiotensin System Inhibitors in Long-Term Oncologic Outcomes of Patients With Stage II/III Colon Cancer and Hypertension: A Target Trial Emulation. PMID 42081750 · JCO Oncol Pract · 2026-May-04 The study is a retrospective observational cohort, not a randomized controlled trial. It does not meet the required criteria for a Phase III/IIIb or Phase II/III randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
From diabetes to tumor growth: unravelling the impact of glucose-lowering therapies. PMID 42081011 · Endocrine · 2026-May-04 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Intraoperative endoscopic pylorus dilatation during minimally invasive Ivor Lewis oesophagectomy to prevent delayed gastric conduit emptying (DGCE): protocol for the WIDE randomised controlled trial. PMID 42082244 · BMJ Open · 2026-May-03 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Doublet versus triplet therapy in Indian patients with locally advanced & metastatic gall bladder cancer: a randomised trial. PMID 42069801 · Sci Rep · 2026-May-02 The record is an oncology randomized trial with drug interventions and primary time-to-event endpoints (PFS, OS). However, the explicit trial phase (III/IIIb or II/III) is not provided in the title, abstract, or metadata, and the deterministic review signals phase3 as false. Therefore, the 'phase3_or_definitive' criterion cannot be established, making the report ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial. PMID 42030965 · Lancet · 2026-May-02 未发现恶性肿瘤人群证据。
H L B
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST). PMID 41880871 · Eur J Cancer · 2026-May-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Stereotactic body radiotherapy versus hepatic resection for recurrent small hepatocellular carcinoma: A post-hoc analysis with propensity score adjustment from two randomized trials. PMID 41833569 · Eur J Cancer · 2026-May-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Tumor burden in metastatic colorectal cancer quantified using deep learning models: Prognostic value and maintenance treatment benefit in the CAIRO3 trial. PMID 41819026 · Eur J Cancer · 2026-May-02 The record is from a randomized, drug-intervention, oncology trial with time-to-event endpoints, but the specific analysis presented is an exploratory biomarker subgroup analysis, not the primary or key secondary result of the trial.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Neoadjuvant chemotherapy for soft-tissue sarcoma of the extremities: A post-hoc Sarculator-based risk analysis of the EORTC 62961-ESHO 95 randomized trial. PMID 42035475 · Cancer · 2026-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Neoadjuvant Immunotherapy and Chemoimmunotherapy Regimens in Head and Neck Cancer: A Systematic Review and Meta-Analysis. PMID 41817516 · JAMA Otolaryngol Head Neck Surg · 2026-May-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
More Questions Than Answers in Trial of GRAIL's Galleri. PMID 41817436 · Cancer Discov · 2026-May-01 The record describes a randomized, controlled trial of a diagnostic test (Galleri) for early cancer detection, not a therapeutic drug intervention. The primary endpoint is a reduction in late-stage cancers, which is not a time-to-event efficacy endpoint (like OS, PFS, etc.) as required. Phase is not definitively established as Phase III/IIIb or Phase II/III. Therefore, it is ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Characteristics of Participants Screened and Randomized to the Melanoma Self Surveillance Trial. PMID 41811339 · JAMA Dermatol · 2026-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Outcomes of Older Adults With Advanced Cancer Who Prefer Quality of Life vs Prolonging Survival: A Secondary Analysis of the GAP70+ Cluster Randomized Clinical Trial. PMID 41784985 · JAMA Oncol · 2026-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Spatially resolved transcriptomics identifies tumor-stroma-immune networks and therapeutic targets in endocrine-resistant advanced breast cancer treated with Everolimus+Letrozole: insights from the MIRACLE trial. PMID 41720449 · Cancer Lett · 2026-May-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical Trial. PMID 41706486 · JAMA Cardiol · 2026-May-01 This is a randomized, open-label Phase II trial (based on sample size and design, not explicitly Phase III) comparing GnRH agonist vs antagonist in men with prostate cancer. The primary endpoint is change in coronary plaque volume (a surrogate/imaging endpoint), not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. No Kaplan-Meier curves or hazard ratios for time-to-event outcomes are reported. It is a cardiovascular safety/biological study, not a definitive efficacy trial for oncologic endpoints.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -